Pam Schumann is an accomplished entrepreneur healthcare leader, including nearly 20 years in technology-enabled, consumer-driven women’s health. She was recently named CEO of Future Fertility, an AI startup focusing on improving IVF outcomes and offering patients personalized feedback on their fertility potential. Pam will bring her experience in bringing disruptive products to market and her passion for improving the IVF patient experience as they launch the first AI software analysis tool to non-invasively evaluate the quality of human oocytes (eggs), creating the only objective classification and prediction tool for an oocyte. Its patented AI machine “Violet” can instantaneously analyze the quality of an egg and can predict embryo development with 67% accuracy.
Prior to joining Future Fertility, Pam served as President of IntegraMed Fertility for where she was responsible for driving long term growth and profitability including launching and managing the company’s $32M Financial Services and $6M Pharmaceutical business units.
Pam sits on the board of RESOLVE, The National Infertility Association whose mission is ensuring that all people challenged in their family building journey reach resolution through being empowered by knowledge, supported by community, united by advocacy, and inspired to act.